Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

Post time 2024-4-20 13:42:04

journal：JAMA Oncology

Authors：Kohei Shitara; Eric Van Cutsem; Yung-Jue Bang; Charles Fuchs; Lucjan Wyrwicz; Keun-Wook Lee; Iveta Kudaba; Marcelo Garrido; Hyun Cheol Chung; Jeeyun Lee; Hugo Raul Castro; Wasat Mansoor; Maria Ignez Braghiroli; Nina Karaseva; Christian Caglevic; Luis Villanueva; Eray Goekkurt; Hironaga Satake; Peter Enzinger; Maria Alsina; Al Benson; Joseph Chao; Andrew H. Ko; Zev A. Wainberg; Uma Kher; Sukrut Shah; S. Peter Kang; Josep Tabernero

Published date：2020-10-1

DOI：10.1001/jamaoncol.2020.3370

PDF link：https://jamanetwork.com/journals ... 619718164.61751.pdf

Article link：http://dx.doi.org/10.1001/jamaoncol.2020.3370

Article Source：American Medical Association (AMA)。

Remark：

Post time 2024-4-20 13:42:05

: This post has been completed
Completed attachments will be deleted within 24 hours.

[JAMA] Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[JAMA] Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer Copy